Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2016 071 477.9 |
96 | EP file number | EAKZ | 16 71 9611.2 |
86 | WO file number | WAKZ | PCT/US2016/026655 |
97 | EP publication number | EPN | 3280729 |
87 | WO publication number | WPN | 2016164731 |
54 | Designation/title | TI | CD20-THERAPIEN, CD22-THERAPIEN UND KOMBINATIONSTHERAPIEN MIT EINER ZELLE ZUR EXPRESSION DES CHIMÄREN ANTIGEN-REZEPTORS (CAR) CD19 |
51 | IPC main class | ICM (ICMV) | C07K 14/725 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | C07K 16/28 (2006.01), C12N 5/0783 (2010.01), A61K 39/00 (2006.01) |
22 | DE application date | DAT | Apr 8, 2016 |
96 | EP application date | EAT | Apr 8, 2016 |
86 | WO application date | WAT | Apr 8, 2016 |
43 | Date of first publication | OT | Oct 13, 2016 |
| Date of publication of grant | PET | Apr 27, 2022 |
71/73 | Applicant/owner | INH | Novartis AG, Basel, CH; The Trustees of The University of Pennsylvania, Philadelphia, PA, US |
72 | Inventor | IN | BITTER, Hans, Lincoln, MA 01773, US; BORDEAUX, Jennifer, Mary, Carlsbad, CA 92008, US; BRANNETTI, Barbara, 4056 Basel, CH; BROGDON, Jennifer, Cambridge, MA 02139, US; DAKAPPAGARI, Naveen, Kumar, Carlsbad, CA 92008, US; GILL, Saar, Philadelphia, PA 19106, US; HIGHFILL, Steven, Bethesda, MD 20814, US; HUANG, Lu, Cambridge, MA 02139, US; JUNE, Carl, H., Merion Station, PA 19066, US; KIM, Ju, Young, Carlsbad, CA 92008, US; LEI, Ming, Cambridge, MA 02139, US; LI, Na, Cambridge, MA 02139, US; LOEW, Andreas, Somerville, MA 02143, US; ORLANDO, Elena, Somerville, MA 02143, US; RUELLA, Marco, PA 19143, US; TRAN, Thai, Carlsbad, CA 92008, US; ZHANG, Jimin, Cambridge, MA 02139, US; ZHOU, Li, Cambridge, MA 02139, US |
74 | Representative | VTR | Mathys & Squire Europe Patentanwälte Partnerschaft mbB, 80333 München, DE |
| Address for service | | Mathys & Squire Europe Patentanwälte Partnerschaft mbB, 80333 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201562144497 P Apr 8, 2015
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201562144639 P Apr 8, 2015
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201562207255 P Aug 19, 2015
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201562144615 P Apr 8, 2015
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201562263423 P Dec 4, 2015
|
| Due date | FT FG | Apr 30, 2026 Annual fee for the 11th year
Patent fees |
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000003280729A2 Searchable text:
EP000003280729A2 Original document:
EP000003280729B1 Searchable text:
EP000003280729B1 Original document:
WO002016164731 Searchable text:
WO002016164731 |
43 | Date of first publication | EVT | Oct 13, 2016 |
| Date of the first transfer into DPMAregister | EREGT | Feb 14, 2018 |
| Date of the (most recent) update in DPMAregister | REGT | Apr 18, 2025 (Show all update days)(Hide all update days)- Apr 18, 2025
- Procedures: Procedure relating to EP application, EPO publication of mention of grant , 27.04.2022: new
- Procedures: Procedure relating to EP application, EPO publication of mention of grant , 27.04.2022: deleted
- Mar 26, 2025
- Jun 11, 2024; May 8, 2024; Mar 26, 2024; Feb 1, 2024; Apr 8, 2023; Mar 30, 2023; Mar 9, 2023; Jul 26, 2022; May 10, 2022; Apr 7, 2022; Mar 31, 2022
- Historical data not available for this/these date(s)
- Feb 14, 2018
- Date of the first transfer into DPMAregister
|